Journal of Clinical Epidemiology
Volume 59, Issue 11 , Pages 1162-1168 , November 2006

Empirical-Bayes adjustment improved conventional estimates in postmarketing drug-safety studies

  • Vincenzo Bagnardi

      Affiliations

    • Department of Statistics, University of Milan-Bicocca, Milan, Italy
    • ,
  • Edoardo Botteri

      Affiliations

    • Department of Statistics, University of Milan-Bicocca, Milan, Italy
    • Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    • ,
  • Giovanni Corrao

      Affiliations

    • Department of Statistics, University of Milan-Bicocca, Milan, Italy
    • Corresponding Author InformationCorresponding author. Dipartimento di Statistica, Università degli Studi di Milano-Bicocca, Via Bicocca degli Arcimboldi 8, 20126 Milano, Italy. Tel.: +39-02-64485854; fax: +39-02-6473312.

,Accepted 23 February 2006.

References 

  1. Strom BL. Pharmacoepidemiology. 3rd ed.. New York: John Wiley & Sons; 2000;
  2. Thomas DC, Siemiatycki J, Dewar R, Robins J, Goldberg M, Armstrong BG. The problem of multiple inference in studies designed to generate hypotheses. Am J Epidemiol. 1985;122:1080–1095
  3. De Roos AJ, Poole C, Teschke K, Olshan F. An application of hierarchical regression in the investigation of multiple paternal occupational exposures and neuroblastoma in offspring. Am J Ind Med. 2001;39:477–486
  4. Rothman KJ. No adjustment are needed for multiple comparisons. Epidemiology. 1990;1:43–46
  5. Greenland S, Robins J. Empirical-Bayes adjustments for multiple comparisons are sometimes useful. Epidemiology. 1991;2:244–251
  6. Greenland S. Methods for epidemiologic analysis of multiple exposure: a review and comparative study of maximum-likelihood, preliminary-testing, and empirical-Bayes regression. Stat Med. 1993;12:717–736
  7. Greenland S, Poole C. Empirical-Bayes and semi-Bayes approaches to occupational and environmental hazard surveillance. Arch Environ Health. 1994;48:9–16
  8. Carlin BP, Louis TA. Bayes and empirical Bayes methods for data analysis. 2nd ed.. New York: Chapman & Hall/CRC; 2000;
  9. Aickin M. Bayes without priors. J Clin Epidemiol. 2004;57:4–13
  10. Steenland K, Bray I, Greenland S, Boffetta P. Empirical-Bayes adjustment for multiple results in hypothesis-generating or surveillance studies. Cancer Epidemiol Biomarkers Prev. 2000;9:895–903
  11. Good I. On estimation of small frequencies in contingency tables. J R Stat Society B. 1956;18:113–124
  12. Efron B, Morris C. Stein's estimation rule and its competitors: an empirical Bayes approach. J Am Stat Assoc. 1973;68:117–130
  13. Greenland S. Principles of multilevel modeling. Int J Epidemiol. 2000;29:158–167
  14. Hung RJ, Brennan P, Malaveille C, Porru S, Donato F, Boffetta P, et al. Using hierarchical modeling in genetic association studies with multiple markers: application to a case–control study of bladder cancer. Cancer Epidemiol, Biomarkers Prev. 2004;13:1013–1021
  15. Witte JS, Greenland S, Haile RW, Bird CL. Hierarchical regression analysis applied to a study of multiple dietary exposures and breast cancer. Epidemiology. 1994;5:612–621
  16. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system (with discussion). Am Stat. 1999;53:177–202
  17. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 2002;45:415–427
  18. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-arrhythmic drugs that prolong the QT interval or induce torsade de pointes. Drug Saf. 2002;25:263–286
  19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  20. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med. 1999;18:321–359
  21. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589–624
  22. Greenland S. Second-stage least squares versus penalized quasi-likelihood for fitting hierarchical models in epidemiologic analyses. Stat Med. 1997;16:515–526
  23. SAS Institute, Inc. . SAS/IML Software: usage and reference, version 6. Cary, NC: SAS Institute Inc.; 1985;
  24. Ohtani H, Taninaka C, Hanada E, Kotaki H, Sato H, Sawada Y, et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother. 2000;44:2630–2637
  25. Milberg P, Eckardt L, Bruns H-J, Biertz J, Ramtin S, Reinsch N, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early after depolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002;303:218–225
  26. Clark DW, Layton D, Wilton LV, Pearce GL, Shakir SAW. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials. Drug Saf. 2001;24:1143–1154
  27. Kang J, Wang L, Chen X-L, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59:122–126
  28. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21:1468–1472
  29. Owens RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy. 2002;22:663–668
  30. Greenland S. A semi-Bayes approach to the analysis of correlated multiple associations, with application to an occupational cancer-mortality study. Stat Med. 1992;11:219–230
  31. Leufkens HG, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol. 1994;46:433–437
  32. McMahon AD, Evans JMM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 1998;7:275–280
  33. Evans JMM, MacDonalds M. Misclassification and selection bias in case–control studies using an automated database. Pharmacoepidemiol Drug Saf. 1997;6:313–318
  34. van Staa TP, Abenhaim L, Leufkens H. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. J Clin Epidemiol. 1994;47:183–189
  35. Eland IA, Huerta-Alvarez C, Stricker BHC, Garcia-Rodriguez LA. The risk of acute pancreatitis associated with acid suppressing drugs. Br J Clin Pharmacol. 2000;49:473–478
  36. Walker AM. Confounding by indication. Epidemiology. 1996;7:335–336
  37. Wen SW, Kramer MS. Uses of ecologic studies in the assessment of intended treatment effects. J Clin Epidemiol. 1999;52:7–12

PII: S0895-4356(06)00160-0

doi: 10.1016/j.jclinepi.2006.02.019

Journal of Clinical Epidemiology
Volume 59, Issue 11 , Pages 1162-1168 , November 2006

Article Tools

* Image Usage & Resolution